Place of probiotics

Current Opinion in Critical Care

Volumn 11, Issue 4, 2005, Pages 318-325

  Meier, Rémy ^a,b   Steuerwald, Michael ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b Kantonsspital Liestal   (Switzerland)

Author keywords

Crohn's disease; Infectious diarrhoea; Major surgery; Pancreatitis; Pouchitis; Probiotics; Synbiotics; Ulcerative colitis

Indexed keywords

GLUTAMINE; PLACEBO; PROBIOTIC AGENT;

ACUTE PANCREATITIS; CLINICAL TRIAL; CROHN DISEASE; DIARRHEA; DRUG EFFECT; ENTERITIS; GASTRECTOMY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; ILEITIS; IMMUNE SYSTEM; INTESTINE INFECTION; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS BULGARICUS; LACTOBACILLUS PLANTARUM; LIVER TRANSPLANTATION; MUCOSA; NONHUMAN; NUTRITIONAL SUPPORT; PANCREAS NECROSIS; PANCREAS RESECTION; REVIEW; STREPTOCOCCUS THERMOPHILUS; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; CRITICAL CARE; CROHN DISEASE; DYSENTERY; GASTROINTESTINAL DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; PERIOPERATIVE CARE; POUCHITIS; PROBIOTICS;

EID: 24344436005     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/01.ccx.0000166396.42894.60     Document Type: Review

References (86)

1. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126:1620-1633. This is a very concise and critical review of the role of intestinal bacteria and the clinical efficacy of different probiotics in IBD.
2. Otte JM, Podolsky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 2004; 286:G613-G626. This is a new report on protection of intestinal epithelial cell tight junctions by probiotics.
3. Ankur S, Yan F, Rao RK, Polk DB. Probiotic Lactobacillus GG secretory factors ameliorate hydrogen peroxide-induced disruption of intestinal epithelial tight junction. Gastroenterology 2004; 126(suppl 2):A515.
4. Yan F, Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem 2002; 277:50959-50965 Epub 2002 Oct 21.
5. Mack DR, Ahrne S, Hyde L, et al. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut 2003; 52:827-833.
6. Smits HH, van Beelen AJ, Hessle C, et al. Commensal Gram-negative bacteria prime human dendritic cells for enhanced IL-23 and IL-27 expression and enhanced Th1 development. Eur J Immunol 2004; 34:1371-1380. Excellent report on the role of gram-negative bacteria on dendritic cells and the induction of a T-helper type 1 inflammatory response.
7. Karlsson H, Larsson P, Wold AE, Rudin A. Pattern of cytokine responses to gram-positive and gram-negative commensal bacteria is profoundly changed when monocytes differentiate into dendritic cells. Infect Immun 2004; 72:2671-2678. Excellent explanation of the interaction between dendritic cells and the commensal bacteria in the regulation of the intestinal immune system.
8. Braat H, de Jong EC, van den Brande JM, et al. Dichotomy between Lactobacillus rhamnosus and Klebsiella pneumoniae on dendritic cell phenotype and function. J Mol Med 2004; 82:197-205. Epub 2003 Dec 13.
9. Drakes M, Blanchard T, Czinn S. Bacterial probiotic modulation of dendritic cells. Infect Immun 2004; 72:3299-3309. This report confirms that dendritic cell phenotype and cytokine production profile are both modulated by commensal and probiotic bacteria.
10. Macpherson AJ, Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 2004; 303:662-665. Excellent explanation of the role of dendritic cells in regulating local IgA production.
11. Salminen S, Isolauri E, Salminen E. Clinical use of probiotics for stabilizing the gut mucosal barrier: successful strains and future challenges. Antonie Van Leeuwenhoek 1996; 70:347-358.
12. Eckmann L. Innate immunity and mucosal bacterial interactions in the intestine. Curr Opin Gastroenterol 2004; 20:82-88. This is a good and comprehensive review on TLR receptors, NOD proteins, and defensins.
13. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003; 52:988-997.
14. Madsen K, Jijon H, Yeung H, et al. DNA from probiotic bacteria exerts anti-inflammatory actions on intestinal epithelial cells by inhibition of NF-kappa B. Gastroenterology 2002; 122:A64.
15. Kelly D, Campbell JI, King TP, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 2004; 5:104-112; Epub 2003 Dec 21. This study demonstrated the bacterial inhibition of nuclear factor-κB activation is mediated through peroxisome proliferator activated receptor-γ.
16. Pena JA, Versalovic J. Lactobacillus rhamnosus GG decreases TNF-alpha production in lipopolysaccharide-activated murine macrophages by a contact-independent mechanism. Cell Microbiol 2003; 5:277-285.
17. Haller D, Serrant P, Peruisseau G, et al. IL-10 producing CD14low monocytes inhibit lymphocyte-dependent activation of intestinal epithelial cells by commensal bacteria. Microbiol Immunol 2002; 46:195-205.
18. Mahida YR, Rolfe VE. Host-bacterial interactions in inflammatory bowel disease. Clin Sci (Lond) 2004; 107:331-341. This is a good and comprehensive review.
19. Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis 2004; 10:286-299. This is a good and comprehensive review.
20. Kruis W. Review article: antibiotics and probiotics in inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20(Suppl 4):75-78. This is a good and comprehensive review.
21. Shibolet O, Karmeli F, Eliakim R, et al. Variable response to probiotics in two models of experimental colitis in rats. Inflamm Bowel Dis 2002; 8:399-406.
22. Fujiwara M, Kaneko T, Iwana H, et al. Inhibitory effects of Bifidobacterium Ion-gum on experimental ulcerative colitis induced in mice by synthetic dextran sulfate sodium. Digestion 2003; 67:90-95.
23. Konrad A, Mahler M, Flogerzi B, et al. Amelioration of murine colitis by feeding a solution of lysed Escherichia coli. Scand J Gastroenterol 2003; 38:172-179.
24. Dieleman LA, Goerres MS, Arends A, et al. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 2003; 52:370-376.
25. Setoyama H, Imaoka A, Ishikawa H, Umesaki Y. Prevention of gut inflammation by Bifidobacterium in dextran sulfate-treated gnotobiotic mice associated with Bacteroides strains isolated from ulcerative colitis patients. Microbes Infect 2003; 5:115-122.
26. Hoentjen F, Harmsen HJ, Braat H, et al. Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice. Gut 2003; 52:1721-1727.
27. Schultz M, Strauch UG, Linde HJ, et al. Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Clin Diagn Lab Immunol 2004; 11:372-378. This excellent study provides more information on mechanisms of changing cytokines and intestinal inflammation in experimental colitis models.
28. Osman N, Adawi D, Ahrne S, et al. Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium. Dig Dis Sci 2004; 49:320-327. This study demonstrated again the role of bacterial translocation in the pathogen-esis of IBD.
29. Araki Y, Andoh A, Takizawa J, et al. Clostridium butyricum, a probiotic derivative, suppresses dextran sulfate sodium-induced experimental colitis in rats. Int J Mol Med 2004; 13:577-580.
30. Dieleman LA, Hoentjen F, Qian BF, et al. Reduced ratio of protective versus proinflammatory cytokine responses to commensal bacteria in HLA-B27 transgenic rats. Clin Exp Immunol 2004; 136:30-39. This study showed the importance of intestinal bacteria in the pathogenesis of IBD. In a specific pathogen-free environment, there is a shift to proinflammatory cytokine production compared with a germ-free environment.
31. McCarthy J, O'Mahony L, O'Callaghan L, et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003; 52:975-980.
32. -/- mice colitis was attenuated.
33. Rachmilewitz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004; 126:520-528. This study demonstrated elegantly that probiotic DNA alone is able to prevent and treat acute experimental colitis by TLR9 and MyD88 signalling processes.
34. Jijon H, Backer J, Diaz H, et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 2004; 126:1358-1373. This study gives further evidence that isolated probiotic DNA inhibits experimental colitis by blocking nuclear factor-κB activation.
35. Rembacken BJ, Snelling AM, Hawkey PM, et al. Nonpathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet 1999; 354:635-639.
36. Ishikawa H, Akedo I, Umesaki Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003; 22:56-63.
37. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15:697-698.
38. Borody TJ, Warren EF, Leis S, et al. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003; 37:42-47.
39. Cui HH, Chen CL, Wang JD, et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol 2004; 10:1521-1525.
40. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53:1617-1623. This is an important large double-blind, double-dummy study showing that E. coli Nissle is as active as mesalazine in maintaining remission in ulcerative colitis.
41. Shen B, Achkar JP, Connor JT, et al. Modified pouchitis disease activity index: a simplified approach to the diagnosis of pouchitis. Dis Colon Rectum 2003; 46:748-753.
42. Hata K, Watanabe T, Shinozaki M, Nagawa H. Patients with extraintestinal manifestations have a higher risk of developing pouchitis in ulcerative colitis: multivariate analysis. Scand J Gastroenterol 2003; 38:1055-1058.
43. Gionchetti P, Amadini C, Rizzello F, et al. Diagnosis and treatment of pouchitis. Best Pract Res Clin Gastroenterol 2003; 17:75-87.
44. Mahadevan U, Sandborn WJ. Diagnosis and management of pouchitis. Gastroenterology 2003; 124:1636-1650.
45. Gionchetti P, Rizzello F, Venturi A, et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999; 13:713-718.
46. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:305-309.
47. Guslandi M. Probiotics for chronic intestinal disorders. Am J Gastroenterol 2003; 98:520-521.
48. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124:1202-1209.
49. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53:108-114. This study confirms again that probiotic therapy with a combination of different strains can maintain remission in recurrent or refractory pouchitis.
50. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal barrier function. Gastroenterology 2001; 121:580-591.
51. Gosselink MP, Schouten WR, van Lieshout LM, et al. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004; 47:876-884. [Epub ahead of print.] This study confirms that a single probiotic strain is able to delay the first onset of pouchitis.
52. Kuisma J, Mentula S, Jarvinen H, et al. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003; 17:509-515.
53. Laake KO, Line PD, Aabakken L, et al. Assessment of mucosal inflammation and circulation in response to probiotics in patients operated with ileal pouch anal anastomosis for ulcerative colitis. Scand J Gastroenterol 2003; 38:409-414.
54. Seksik P, Rigottier-Gois L, Gramet G, et al. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 2003; 52:237-242.
55. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122:44-54.
56. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000; 45:1462-1464.
57. Campieri M, Rizzello F, Venturi A, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomized controlled study vs. mesalamine. Gastroenterology 2000; 118:G4179.
58. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002; 51:405-409.
59. Schultz M, Timmer A, Herfarth HH, et al. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 2004; 4:5. This study confirms that a single probiotic strain shows no benefit in inducing or maintaining medically induced remission in Crohn's disease.
60. Sullivan A, Nord CE. Probiotics in human infections. J Antimicrob Chemother 2002; 50:625-627.
61. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361:512-519.
62. Surawicz CM. Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans. Best Pract Res Clin Gastroenterol 2003; 17:775-783.
63. Allen SJ, Okoko B, Martinez E, et al. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2004; 2:CD003048. This is an excellent analysis showing the effectiveness of probiotics in treating acute infectious diarrhoea in adults and children.
64. Guandalini S, Pensabene L, Zikri MA, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr 2000; 30:54-60.
65. Szajewska H, Mrukowicz JZ. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr 2001; 33(Suppl 2):S17-S25.
66. Huang JS, Bousvaros A, Lee JW, et al. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci 2002; 47:2625-2634.
67. Van Niel CW, Feudtner C, Garrison MM, Christakis DA. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics 2002; 109:678-684.
68. Salazar-Lindo E, Miranda-Langschwager P, Campos-Sanchez M, et al. Lactobacillus casei strain GG in the treatment of infants with acute watery diarrhea: a randomized, double-blind, placebo controlled clinical trial. BMC Pediatr 2004; 4:18. This study shows that in short duration of acute watery diarrhoea, probiotics are not effective.
69. Costa-Ribeiro H, Ribeiro TC, Mattos AP, et al. Limitations of probiotic therapy in acute, severe dehydrating diarrhea. J Pediatr Gastroenterol Nutr 2003; 36:112-115.
70. Sudarmo SM, Ranuh RG, Rochim A, Soeparto P. Management of infant diarrhea with high-lactose probiotic-containing formula. Southeast Asian J Trop Med Public Health 2003; 34:845-848.
71. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002; 324:1361.
72. Cremonini F, Di Caro S, Nista EC, et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2002; 16:1461-1467.
73. Plummer S, Weaver MA, Harris JC, et al. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 2004; 7:59-62. This study confirms again an effect of probiotics in decreasing C. difficile toxin-positive diarrhoea in elderly patients receiving antibiotics.
74. Erdeve O, Tiras U, Dallar Y. The probiotic effect of Saccharomyces boulardii in a pediatric age group. J Trop Pediatr 2004; 50:234-236. This study confirms again that S. boulardii decreases the rate of diarrhoea in children receiving antibiotics.
75. Schrezenmeir J, Heller K, McCue M, et al. Benefits of oral supplementation with and without synbiotics in young children with acute bacterial infections. Clin Pediatr (Phila) 2004; 43:239-249. This study confirms the positive clinical effects of probiotics on bacterial illness during antibiotic treatment in children.
76. Chouraqui JP, Van Egroo LD, Fichot MC. Acidified milk formula supplemented with bifidobacterium lactis: impact on infant diarrhea in residential care settings. J Pediatr Gastroenterol Nutr 2004; 38:288-292. This report confirms a preventive effect of probiotics on diarrhoea.
77. Rayes N, Seehofer D, Muller AR, et al. Influence of probiotics and fibre on the incidence of bacterial infections following major abdominal surgery: results of a prospective trial [in German]. Z Gastroenterol 2002; 40:869-876.
78. Anderson AD, McNaught CE, Jain PK, MacFie J. Randomised clinical trial of synbiotic therapy in elective surgical patients. Gut 2004; 53:241-245. This excellent study reported no effect on bacterial translocation and clinical benefits with a symbiotic treatment in surgical patients.
79. Howard JC, Reid G, Gan BS. Probiotics in surgical wound infections: current status. Clin Invest Med 2004; 27:274-281.
80. Bengmark S. Ecological control of the gastrointestinal tract: the role of probiotic flora. Gut 1998; 42:2-7.
81. Woodcock NP, McNaught CE, Morgan DR, et al. An investigation into the effect of a probiotic on gut immune function in surgical patients. Clin Nutr 2004; 23:1069-1073. Elegant study investigating intestinal mucosal immune function. There was no clear benefit with a single probiotic strain.
82. Jain P, McNaught CE, Anderson AD, et al. Influence of synbiotic containing Lactobacillus acidophilus La5, Bifidobacterium lactis Bb 12, Streptococcus thermophilus, Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: a randomised controlled trial. Clin Nutr 2004; 23:467-475. This report confirms that a symbiotic preparation changes the microbial composition of the upper gastrointestinal tract and provides further evidence to support the gut-origin sepsis hypothesis.
83. Falcao de Arruda IS, de Aguilar-Nascimento JE. Benefits of early enteral nutrition with glutamine and probiotics in brain injury patients. Clin Sci (Lond) 2004; 106:287-292. A clear clinical benefit was demonstrated with a combination of glutamine and probiotics in patients with brain injury. It is not clear which component is more active here.
84. Olah K, Belagyi T, Issekutz A, et al. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. Br J Surg 2002; 89:1103-1107.
85. Kecskes G, Belagyi T, Olah A. Early jejunal nutrition with combined pre- and probiotics in acute pancreatitis: prospective, randomized, double-blind investigations [in Hungarian]. Magy Seb 2003; 56:3-8.
86. Besselink MG, Timmerman HM, Buskens E, et al. Dutch Acute Pancreatitis Study Group. Probiotic prophylaxis in patients with predicted severe acute pancreatitis (PROPATRIA): design and rationale of a double-blind, placebo-controlled randomised multicenter trial. BMC Surg 2004; 4:12.